Pulmozyme & Treatment Guidelines

Pulmozyme is recommended in regional and national treatment guidelines

  • According to the European CF Society guideline, Pulmozyme is the only mucus-degrading agent that has proven efficacy in CF14
    • In patients, regardless of disease severity, Pulmozyme has demonstrated improvements in lung function and a reduction in pulmonary exacerbations (intermittent episodes of clinical deterioration)14
    • Pulmozyme can reduce lung function decline, according to an analysis of the Epidemiologic Study of Cystic Fibrosis14
    • The effects of treatment are lost when treatment is ceased; therefore, long-term maintenance therapy with Pulmozyme is required14
    • Other mucolytics, such as N-acetyl cysteine, have not been proven to be effective in patients with CF14
    • Link to guideline: https://www.cysticfibrosisjournal.com/article/S1569-1993(14)00085-X/fulltext
       
  • NICE recommends Pulmozyme as the first choice of mucoactive treatment of CF24
    • NICE guideline on diagnosis and management of CF recommends offering Pulmozyme as the first choice of mucoactive agent to patients with CF who have clinical evidence of lung disease before using hypertonic saline24
    • Link to guideline: https://www.nice.org.uk/guidance/ng78/chapter/recommendations
    • Watch this video to learn from an internationally renowned expert about the published NICE guideline and how it impacts clinical practice:
  • Cystic Fibrosis Foundation guideline recommends Pulmozyme in CF patients12
    • For individuals with CF, 6 years of age and older, with asymptomatic or mild lung disease, the CF Foundation recommends the chronic use of dornase alfa to improve lung function and reduce exacerbations12
    • For individuals with CF, 6 years of age and older, with moderate to severe lung disease, the CF Foundation strongly recommends the chronic use of dornase alfa to improve lung function and reduce exacerbations12
    • Link to guideline: https://www.atsjournals.org/doi/full/10.1164/rccm.201207-1160OE

12. Mogayzel PJ et al and Pulmonary Clinical Proactice Gidelines Committee. Cystic Fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-689.

14.  Smyth AR et al. European Cystic Fibrosis Society standards of care; best practice guidelines. J Cyst Fibros. 2014; (13 Suppl 1):S23-42.

24. National Institute for Health and Care Excellence (October 2017). Cystic fibrosis: diagnosis and management. https://www.nice.org.uk/guidance/ng78 . Accessed 21/8/18